Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon 5051 - Cell signaling and Oncology Library.xls |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 2992 | CTx-0294885 | Broad-spectrum kinase inhibitor | €90.00 | |
| 1965 | CX 4945 hydrochloride | Inhibitor of Casein kinase 2 (CK2) | €90.00 | |
| 2305 | CX 6258 hydrochloride | Pim kinase inhibitor | €99.00 | |
| 3235 | Dacomitinib | Potent irreversible pan-HER inhibitor | €60.00 | |
| 1392 | Dasatinib | Bcr-Abl and Src tyrosine kinase inhibitor | €90.00 | |
| 2123 | DCC 2036 | An orally active Bcr-ABL inhibitor | €110.00 | |
| 2574 | Defactinib | Orally available second generation inhibitor of FAK and PYK2 | €80.00 | |
| 1682 | Enzastaurin | PKC-β inhibitor | €95.00 | |
| 2331 | FRAX 486 | Bioavailable, brain penetrating inhibitor of p21-activated kinases (PAKs) | €90.00 | |
| 2348 | GNE 7915 | Potent, selective, metabolically stable, and brain-penetrable LRRK2 inhibitor | €110.00 | |
| 1882 | GNF 2 | Inhibitor of Bcr-Abl tyrosine kinase | €110.00 | |
| 2466 | Gö 6983 | Broad spectrum PKC inhibitor lacking inhibitory effect for PKCμ | €90.00 | |
| 2181 | GSK 2578215A | Potent and highly selective LRRK2 inhibitor | €125.00 | |
| 1167 | GSK 269962A | ROCK1 and ROCK2 inhibitor | €65.00 | |
| 2713 | GSK 2982772 | Specific inhibitor of RIP1 kinase | €115.00 | |
| 3717 | GSK2256098 | FAK inhibitor | Inquire | |
| 2608 | GSK481 | Potent inhibitor of RIP1 kinase and TNF induced inflammation | €95.00 | |
| 3627 | Harmine | Potent, selective and ATP-competitive DYRK1A inhibitor | €50.00 | |
| 2511 | IM 12 | GSK-3β inhibitor attenuating neuronal differentiation of human NPCs | €95.00 | |
| 1394 | Imatinib mesylate | Bcr-Abl, c-KIT and PDGFR kinase inhibitor | €60.00 | |
| 2121 | INNO 406 | Dual Bcr-Abl and Lyn kinase inhibitor | €85.00 | |
| 3557 | KPT-9274 | Orally bioavailable dual PAK4/NAMPT inhibitor | €130.00 | |
| 1395 | Lapatinib ditosylate | EGFR and ErbB-2/HER2 tyrosine kinase inhibitor | €80.00 | |
| 2297 | LH 846 | Inhibitor of Casein kinase 1 (CK1δ) | €95.00 | |
| 2493 | LRRK2-IN-1 | Potent, ATP-competitive and selective inhibitor of LRRK2 | €85.00 | |
| 2362 | LY 333531 hydrochloride | PKC-β inhibitor | €80.00 | |
| 1401 | LY 333531 mesylate | PKC-β inhibitor | €80.00 | |
| 5011 | Naive Stem Cell 5i inhibitor Set | Set of five inhibitors for the induction and maintenance of human naive stem cell pluripotency | €200.00 | |
| 5010 | Naive Stem Cell NHSM inhibitor Set | Set of inhibitors for isolation, generation, derivatization and stabilization of naive hPSCs | €230.00 | |
| 1258 | Necrostatin-1 | RIP1 inhibitor | €95.00 | |